Every Form 4 that ORGANON & CO (OGN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow OGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OGN filings page.
Organon & Co. executive Juan Camilo Arjona Ferreira, Head of R&D & CMO, reported an option-style event involving restricted stock units. On August 11, 2026 he exercised or converted 11,519 restricted stock units into the same number of common shares. In a related transaction, 4,134 common shares were delivered or withheld at $13.62 per share for payment of exercise price or tax liability. Footnotes state each restricted stock unit represents a contingent right to one common share and vesting occurs in three equal installments with the final vesting on August 11, 2026.
Organon & Co. executive Juliana Papa Drinane, Head of Mfg & Supply, reported selling 14,761 shares of common stock on 2026-08-05 at $13.57 per share in an open-market or private transaction. Following the sale, she directly holds 18,474.703 shares of Organon common stock.
Organon & Co. director Shalini Sharp reported a routine compensation grant of phantom stock units. She received 17,857.143 phantom stock units on the transaction date, each economically equivalent to one share of Organon common stock on a 1-for-1 basis at a reference value of $13.44 per unit.
Following this grant, her holdings of phantom stock units increased to 81,495.885. These units were granted under the Organon Non-Employee Director Savings Plan and are payable in cash after her termination of service as a director, in accordance with the plan’s terms. Holdings also reflect phantom stock acquired through dividend reinvestment on specified past dates.
Sequeira Ramona reported acquisition or exercise transactions in this Form 4 filing.
Organon & Co. director Ramona Sequeira received a grant of phantom stock units as compensation. On this Form 4, she was awarded 17,857.143 phantom stock units tied to Organon common stock at an indicated value of $13.44 per unit. Each unit is economically equivalent to one share of common stock but is payable in cash after she leaves the board, under the Organon Non-Employee Director Savings Plan. Following this grant and prior dividend reinvestments, her reported phantom stock holdings total 39,950.644 units.
Patton Cynthia M reported acquisition or exercise transactions in this Form 4 filing.
Organon & Co. director Cynthia M. Patton received a grant of 17,857.143 phantom stock units tied to Organon common stock. Each unit is economically equivalent to one share of common stock on a 1-for-1 basis and references a price of $13.44 per unit.
The award was made under the Organon Non-Employee Director Savings Plan and will be settled in cash after her service as a director ends, according to the plan terms. Following this grant and prior dividend reinvestment accruals, her holdings total 81,141.129 phantom stock units.
Ozuah Philip reported acquisition or exercise transactions in this Form 4 filing.
Organon & Co. director Philip Ozuah received a grant of 17,857.143 phantom stock units tied to Organon common stock. The award was recorded at a reference price of $13.44 per unit and increases his directly held phantom stock position to 81,141.133 units.
Each phantom stock unit is economically equivalent on a 1‑for‑1 basis to one share of Organon common stock but is payable in cash, not stock. The units were granted under the Organon Non-Employee Director Savings Plan and will be settled in cash after his service as a director ends, in line with the plan’s terms.
Leone Deborah R reported acquisition or exercise transactions in this Form 4 filing.
Organon & Co. director Deborah R. Leone received a grant of 17,857.143 phantom stock units linked to Organon common stock. The units were awarded at an indicated value of $13.44 per unit and are economic equivalents of common shares on a 1-for-1 basis.
The award was made under the Organon Non-Employee Director Savings Plan and will be settled in cash after she leaves the board, according to the plan’s terms. After this grant, Leone holds a total of 81,141.135 phantom stock units, including units accumulated through prior dividend reinvestment transactions. This filing reflects director compensation rather than an open-market stock purchase or sale.
LAZARUS ROCHELLE B reported acquisition or exercise transactions in this Form 4 filing.
Organon & Co. director Rochelle B. Lazarus received a grant of phantom stock units as compensation. The award covers 17,857.143 phantom stock units at a reference price of $13.44 per unit, each economically equivalent to one share of Organon common stock on a 1-for-1 basis.
After this grant and prior dividend reinvestment credits, Lazarus now holds a total of 81,141.135 phantom stock units. These units were granted under the Organon Non-Employee Director Savings Plan and will be settled in cash after her service as a director ends, rather than delivering actual shares.
Organon & Co. director Gayle Helene D received a grant of 17,857.143 phantom stock units on June 12, 2026, at an assigned value of $13.44 per unit. Each phantom unit is economically equivalent to one share of Organon common stock and is payable in cash under the Non-Employee Director Savings Plan after her board service ends. Following this award, her holdings total 81,141.134 phantom stock units, including units acquired through prior dividend reinvestment transactions.
Organon & Co. director Alan Ezekowitz received a grant of 17,857.143 phantom stock units on Organon common stock. The units were valued at $13.44 per unit and bring his total phantom stock holdings to 81,141.131 units. Each unit is economically equivalent to one share of Organon common stock and is payable in cash after his service as a director ends under the Organon Non-Employee Director Savings Plan. Holdings also reflect phantom stock acquired through dividend reinvestment on several prior dates.
ESSNER ROBERT reported acquisition or exercise transactions in this Form 4 filing.
Organon & Co. director Robert Essner reported a compensation-related grant of phantom stock units. On June 12, 2026, he was awarded 17,857.143 phantom stock units at a reference value of $13.44 per unit.
Each phantom stock unit is economically equivalent to one share of Organon common stock on a 1-for-1 basis and is payable in cash after his service as a director ends, under the Organon Non-Employee Director Savings Plan. Following this award and prior dividend reinvestment transactions, his holdings total 81,141.129 phantom stock units.
Organon & Co.’s SVP and Corporate Controller, Lynette Holzbaur, reported an amended insider transaction on common stock. The filing now shows an open-market sale of 26,448.366 shares of common stock at $13.3498 per share on May 6, 2026, leaving her with 0 shares directly owned afterward.
The amendment clarifies that this transaction should be treated as a sale (disposition) rather than a purchase as previously reported. It also records the acquisition of 45.939 shares of common stock that had not been required to be reported earlier, categorized as an “other acquisition or disposition.”
Organon & Co. senior vice president and corporate controller Lynette Holzbaur bought Common Stock in the open market. On May 6, 2026, she purchased 26,448.366 shares at an average price of $13.3498 per share. Following this transaction, she directly owns 52,850.793 Common Stock shares.
Organon & Co. interim executive Juliana Papa reported a large equity compensation grant and related vesting activity. On March 31, 2026, she received 125,208 restricted stock units (RSUs), each representing a contingent right to one share of Organon common stock. These RSUs will vest in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
On the same date, previously granted RSUs vested and were converted into common shares through exercises of 6,378 and 10,073 RSUs. To cover tax obligations, 2,185 and 3,451 common shares were withheld at a price of $5.70 per share. After these transactions, Papa directly holds 33,235.703 shares of common stock and 20,148 RSUs.
Organon & Co. Head of R&D & CMO Juan Camilo Arjona Ferreira reported equity compensation and related share movements. On March 31, 2026, he received a grant of 200,333 Restricted Stock Units (RSUs), each representing one share of Organon common stock, vesting in three equal installments on March 31, 2027, 2028, and 2029.
On the same date, he exercised 13,431 RSUs from a prior March 31, 2025 grant, receiving an equal number of common shares. Of these, 4,820 shares of common stock were withheld at $5.70 per share to cover tax obligations. Following these transactions, he directly holds 30,047.477 shares of common stock and 200,333 RSUs.
Organon & Co. executive Daniel Karp reported several equity compensation moves involving Restricted Stock Units (RSUs) and common stock. On March 31, 2026, he received a grant of 100,166 RSUs, each representing a contingent right to one share of Organon common stock. These RSUs vest in three equal installments on March 31, 2027, 2028, and 2029.
On the same date, previously granted RSUs from March 31, 2023 and March 31, 2025 partially vested, converting 11,338 and 6,715 RSUs, respectively, into common shares. To cover tax obligations, 3,554 and 2,105 common shares were withheld at a price of $5.70 per share. After these transactions, Karp directly held 69,547.923 shares of Organon common stock, alongside the new unvested RSU grant.
Organon & Co. Chief Information Officer Rachel A. Stahler reported compensation-related stock activity. She was granted 183,639 restricted stock units (RSUs) on March 31, 2026, each representing a contingent right to one share of Organon common stock, vesting in three equal installments on March 31, 2027, 2028, and 2029.
On the same date, previously granted RSUs from March 31, 2023 and March 31, 2025 vested and were exercised into common shares. A total of 6,463 shares of common stock were withheld at a price of $5.70 per share to cover tax obligations. After these transactions, Stahler directly holds 116,105.292 shares of Organon common stock.
Organon & Co. Chief Financial Officer Matthew M. Walsh reported a series of equity compensation transactions in Organon common stock. On March 31, 2026, he was granted 321,368 restricted stock units (RSUs) and a separate grant of 83,472 RSUs, each RSU representing a contingent right to one share of common stock. These RSUs will vest in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. On the same date, portions of earlier RSU awards granted in 2023 and 2025 vested and were exercised into common stock, while 4,127 and 7,380 shares were withheld at $5.70 per share to cover tax obligations. Following these transactions, Walsh directly holds 212,746 shares of Organon common stock.
Organon & Co. Chief Human Resources Officer Aaron Falcione reported equity compensation activity involving restricted stock units (RSUs) and common stock. On March 31, 2026, he received a grant of 166,944 RSUs, each representing a contingent right to one share of Organon common stock.
The new RSUs vest in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. On the same date, previously granted RSUs vested and were converted into 6,732 and 11,193 shares of common stock. To satisfy tax obligations, 2,306 and 3,834 shares were withheld at a price of $5.70 per share.
After these transactions, Falcione directly owned 101,431.071 shares of Organon common stock and held 166,944 RSUs subject to future vesting.
Organon & Co. general counsel Kirke Weaver reported compensation-related equity activity. On March 31, 2026, Weaver received a grant of 183,639 Restricted Stock Units (RSUs), each representing a contingent right to one share of Organon common stock. These RSUs vest in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
On the same date, previously granted RSUs vested and were exercised into 18,513 shares of common stock. To cover tax obligations, 5,275 shares were withheld at a price based on the March 30, 2026 closing market price of $5.70 per share. After these transactions, Weaver directly owned 92,639.163 shares of Organon common stock.
Organon & Co. executive Vittorio Nisita reported routine equity compensation activity. On March 31, 2026, Nisita received a grant of 125,208 Restricted Stock Units (RSUs), each representing a contingent right to one share of Organon common stock. These RSUs will vest in three equal installments on March 31, 2027, 2028, and 2029.
On the same date, portions of earlier RSU grants from 2023 and 2025 vested, converting into a total of 13,000 shares of common stock. To satisfy tax obligations, 4,453 shares were withheld at a reference price of $5.70 per share, leaving Nisita with 70,619.158 common shares held directly after these transactions.
Organon & Co. senior vice president and corporate controller Lynette Holzbaur reported equity compensation and related share activity. On March 31, 2026, she received grants of 75,125 and 41,736 Restricted Stock Units (RSUs), each RSU representing a contingent right to one share of Organon common stock. These RSUs will vest in three equal installments on March 31, 2027, 2028, and 2029.
The filing also shows vesting of earlier RSU awards from March 31, 2023 and March 31, 2025, with the remaining one‑third of those grants converting into common shares. As part of the vesting, 1,212 and 1,914 shares of common stock were withheld at $5.70 per share to satisfy tax obligations, a non‑market disposition. Following these transactions, Holzbaur holds 26,402.427 shares of Organon common stock directly. The activity reflects routine compensation grants, vesting, and tax withholding rather than open‑market buying or selling.
Organon & Co. interim CEO Joseph T. Morrissey Jr. reported compensation-related equity activity in Organon stock. On March 31, 2026, he received a grant of 333,889 Restricted Stock Units (RSUs), each representing one share of common stock, vesting in three equal installments on March 31, 2027, 2028, and 2029.
He also exercised previously granted RSUs into common stock and had shares withheld to cover tax obligations. In total, 24,584 RSUs were converted into common stock, with 7,005 shares withheld at $5.70 per share for taxes. Following these transactions, he directly holds 123,122.923 shares of Organon common stock and 333,889 RSUs subject to future vesting.
Organon & Co. Chief Information Officer Rachel A. Stahler exercised restricted stock units into common shares and had a portion withheld for taxes. On March 29, 2026, 8,200 restricted stock units converted into 8,200 shares of common stock, reflecting equity compensation vesting.
To cover tax obligations, 2,809 of those shares were automatically withheld at a price of $5.84 per share, rather than sold in the open market. After these routine compensation and tax-withholding transactions, Stahler directly held 103,701.292 shares of Organon common stock.
Organon & Co. SVP and Corporate Controller Lynette Holzbaur exercised 5,319 restricted stock units into common stock. Each RSU converted into one share, reflecting a scheduled vesting installment. Of the shares received, 1,516 were withheld at $5.84 per share to cover tax obligations.
After these transactions and the addition of 82 shares from dividend equivalents, Holzbaur directly holds 18,561.427 shares of Organon common stock. The activity represents routine equity compensation, combining an RSU vesting event with share withholding for taxes rather than an open‑market trade.
Organon & Co. Executive VP, Corp. Dev. Daniel Karp exercised 14,184 Restricted Stock Units into common stock. The RSUs converted one-for-one into Organon shares at a stated price of $0.00 per unit.
To satisfy tax obligations, 4,446 shares of common stock were withheld at a reference price of $5.84 per share, based on the closing market price on March 27, 2026 as required under the plan. Following these transactions, Karp directly holds 57,153.923 shares of Organon common stock, which includes 746.463 shares acquired from dividend equivalents net of withholding tax. The RSUs vest and are distributed in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027.
Organon & Co. general counsel Kirke Weaver exercised restricted stock units into common shares and had shares withheld for taxes. On March 29, 2026, 7,757 restricted stock units converted into 7,757 common shares at a stated price of $0.00 per share. Of these, 2,210 common shares were withheld at $5.84 per share to satisfy tax obligations, a non-market transaction. After these transactions, Weaver directly holds 79,401.163 shares of Organon common stock. The footnotes state each RSU represents one share of common stock and that this RSU award vests in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027.
Organon & Co. executive Nisita Vittorio exercised 5,762 Restricted Stock Units (RSUs) into common stock and covered taxes with shares. Each RSU converts into one share of Organon common stock. After these transactions, Vittorio directly holds 62,072.158 shares of Organon common stock.
A total of 1,974 common shares were withheld at a price of $5.84 per share to satisfy tax obligations, which is treated as a tax-withholding disposition rather than an open-market sale. The RSUs vest in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027, aligning share delivery with the executive’s multi‑year compensation schedule.
Organon & Co.'s Interim Head of Manufacturing & Supply, Juliana Papa Drinane, exercised 7,979 Restricted Stock Units into common stock on March 29, 2026. To cover taxes, 2,733 shares were withheld at $5.84 per share. She now directly holds 22,420.703 Organon common shares, reflecting a routine compensation-related equity increase.
Organon & Co. Head of R&D & CMO Juan Camilo Arjona Ferreira exercised restricted stock units into common shares as part of equity compensation. On March 29, 2026, 8,865 RSUs converted into 8,865 shares of common stock at a stated price of $0.00 per share.
To satisfy tax obligations, 3,181 common shares were withheld at $5.84 per share, a non‑market disposition rather than an open‑market sale. After these transactions, he directly holds 21,436.477 common shares. Beneficial ownership was also adjusted to reflect a prior transfer of 13,872 shares under Exchange Act Rule 16a-12 and the addition of 708.122 shares from dividend equivalents.
Organon & Co. Chief Human Resources Officer Aaron Falcione exercised restricted stock units into common shares as part of his equity compensation. On March 29, 2026, 8,422 Restricted Stock Units converted into 8,422 shares of common stock at a conversion price of $0.00 per share.
To cover tax obligations, 2,885 of these shares were disposed of through a tax-withholding transaction at $5.84 per share, rather than through an open-market sale. After these transactions, Falcione directly held 89,646.071 shares of Organon common stock.
Each Restricted Stock Unit represents a right to receive one share of Organon common stock, and these awards vest in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027, aligning the executive’s compensation with the company’s long-term performance.
Organon & Co. Chief Financial Officer Matthew M. Walsh exercised restricted stock units into common shares and had some shares withheld for taxes. On March 29, 2026, 15,071 restricted stock units converted into 15,071 shares of Organon common stock at a stated price of $0.00 per share.
To cover tax obligations, 5,162 of these common shares were withheld at a price of $5.84 per share. After these compensation-related transactions, Walsh directly owned 190,660 shares of Organon common stock. The underlying restricted stock units vest in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027.
Organon & Co. interim CEO Joseph T. Morrissey Jr. exercised 9,752 Restricted Stock Units (RSUs) into common stock on March 29, 2026. Each RSU converts into one share of Organon common stock, and the award vests in three equal installments on March 29, 2025, 2026, and 2027. To satisfy tax obligations related to this vesting, 2,779 common shares were withheld at a reference price of $5.84 per share. After these compensation-related transactions, Morrissey holds 105,543.923 common shares directly, indicating this filing reflects routine equity award vesting and associated tax withholding rather than an open-market stock sale.
Organon & Co. Chief Human Resources Officer Aaron Falcione reported equity compensation activity in company common stock. On February 27, 2026, he acquired 23,805 shares and 6,717 shares at no cost as stock awards tied to performance share units granted in August 2023, following certification of performance goals and related dividend equivalents. To cover tax obligations, he disposed of 8,705 shares at $7.17 and 2,301 shares at $7.23 through tax-withholding dispositions rather than open-market sales. After these transactions, he directly owned 84,109.071 shares of Organon common stock.
Organon & Co. Chief Financial Officer Matthew M. Walsh reported equity compensation activity in common stock. He acquired 42,599 shares and 12,020 shares at no cost upon performance share units and related dividend equivalents vesting. To satisfy tax obligations, he disposed of 14,887 shares at $7.17 and 4,117 shares at $7.23 through tax-withholding transactions, leaving a six-figure direct holding in Organon stock.
Organon & Co. executive Nisita Vittorio reported equity compensation activity involving common stock on February 27, 2026. She received 16,287 shares tied to performance share units granted on August 11, 2023, after performance goals were certified, plus 4,596 additional shares related to dividend equivalents.
To satisfy tax obligations, 6,210 shares at $7.17 and 1,575 shares at $7.23 were disposed of through tax-withholding transactions rather than open-market sales. After these awards and withholdings, she directly held 58,284.158 shares of Organon common stock.
Organon & Co.'s Chief Information Officer Rachel A. Stahler reported equity award activity in the company's common stock. She acquired 23,178 shares and 6,540 shares at no cost, reflecting performance share units granted on August 11, 2023 whose performance-vesting conditions were certified by a board committee, plus related dividend equivalents. To cover tax withholding on these releases, 8,475 shares at $7.17 and 2,240 shares at $7.23 were disposed of through share withholding rather than open-market sales. Following these transactions, she directly owns 98,310.292 shares, including 2,076.678 shares from prior dividend equivalents net of withholding tax.
Organon & Co. general counsel Kirke Weaver reported stock-based compensation and related tax-withholding transactions in company common stock. On February 27, 2026, Weaver acquired 21,925 shares tied to performance share units granted on August 11, 2023, after Organon’s Talent Committee certified that performance goals were met.
Weaver also acquired 6,186 shares representing dividend equivalents on those performance units, and 1,832.163 additional shares from prior dividend equivalents were added to holdings. To cover tax liabilities, 6,815 shares at $7.17 and 1,763 shares at $7.23 were disposed through tax-withholding transactions. Following these movements, Weaver directly owned 73,854.163 common shares.
Organon & Co. interim CEO Joseph T. Morrissey Jr. reported equity compensation-related share movements in Organon common stock. On February 27, 2026, he acquired 27,564 shares tied to performance share units granted on August 11, 2023, after performance goals were certified, and an additional 7,777 shares were granted as related awards and dividend equivalents at no cost.
On the same date, 8,054 shares at $7.17 per share and 2,216 shares at $7.23 per share were surrendered in tax-withholding dispositions to cover exercise price or tax obligations. After these transactions and the inclusion of 1,938.068 dividend-equivalent shares that were not previously reportable, he directly held about 98,571 shares of Organon common stock.
Organon & Co. insider corrects a prior Form 4 filing related to a tax-withholding share sale. The officer, listed as Interim Head of Manufacturing & Supply, clarifies that a November 7, 2025 transaction involving 1,242 shares of Organon common stock at $6.71 per share (transaction code F) should have been reported as a disposal rather than an acquisition. This transaction reflects shares sold to satisfy a tax liability arising from the acquisition of other Organon shares. After properly classifying the sale, the officer’s beneficial ownership is reported as 17,174.703 shares of Organon common stock held directly.
Organon & Co. reported an equity grant to a senior officer through a Form 4 filing. Interim Head of Manufacturing & Supply Juliana Drinane received an award of 65,616 restricted stock units (RSUs) on November 13, 2025. Each RSU converts into one share of Organon common stock, so this grant represents 65,616 potential future shares. The RSUs will vest in three equal installments on November 13, 2026, November 13, 2027, and November 13, 2028, aligning the officer’s compensation with the company’s longer-term performance.
Organon & Co. reported an equity grant to its interim CEO. On November 13, 2025, officer and interim CEO Joseph T. Morrissey, Jr. received 131,233 restricted stock units (RSUs), each convertible into one share of Organon common stock. The RSUs were granted following the company’s earnings release for the quarter ended September 30, 2025. These RSUs vest in three equal installments on November 13, 2026, November 13, 2027, and November 13, 2028. After this grant, Morrissey beneficially owns 131,233 derivative securities directly.
Organon & Co. (OGN) reported an insider purchase on a Form 4. Executive Chair and Director Carrie Smith Cox bought 65,400 shares of common stock on 11/12/2025 at a $7.6721 weighted average price.
The filing notes the shares were acquired in multiple trades within a price range of $7.6630 to $7.6899. Following the transaction, Cox beneficially owned 77,869 shares, held indirectly through an IRA.
Organon & Co. (OGN) reported insider activity by officer Juliana Drinane (Interim Head of Mfg & Supply). On 11/07/2025, 3,626 restricted stock units converted into common stock at $0 per share (transaction code M). The filing also lists a transaction coded F for 1,242 shares at $6.71 per share on the same date. Following the reported transactions, direct beneficial ownership is shown as 19,658.703 common shares.
The RSUs derived from a grant of 10,876 units awarded on November 7, 2023, vesting in three equal annual installments, with the final vesting date on November 7, 2026. Each RSU represents a right to receive one share of Organon common stock.
Organon & Co. (OGN): Insider equity update. On 11/07/2025, the Head of R&D & CMO reported the conversion of restricted stock units into 6,446 shares of common stock at $0 per share (code M). To cover taxes, 2,307 shares were withheld at $6.71 per share (code F). Following these transactions, direct beneficial ownership is 28,916.355 shares.
The filing notes an RSU grant vesting in three installments: 6,446 shares on November 7, 2024; 6,446 shares on November 7, 2025; and 6,447 shares on November 7, 2026. After the reported activity, 6,447 RSUs remain outstanding, expiring on November 7, 2026.
Organon (OGN) SVP and Corporate Controller reported Form 4 activity. On 11/07/2025, 2,417 shares of common stock were acquired at $0 via the conversion of restricted stock units (code M). The filer also disposed of 689 shares at $6.71 (code F). Following these transactions, beneficial ownership stands at 14,676.427 shares (direct).
The related RSU entry shows 2,417 underlying shares converted, with 2,418 RSUs remaining directly beneficially owned. The original grant was 7,252 RSUs on 11/07/2023, vesting one‑third each year through 11/07/2026.
Organon & Co. (OGN) reported an insider equity transaction by its SVP and Corporate Controller. On 11/05/2025, 3,037 shares of common stock were acquired at $0 upon RSU vesting (code M), and 866 shares were disposed at $6.52 for tax withholding (code F). Following these transactions, direct holdings were 12,948.427 shares.
The underlying RSUs vest in three equal installments, beginning on November 5, 2025 and ending on November 5, 2027. Derivative securities beneficially owned after the event totaled 6,076.